Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin plus clopidogrel versus aspirin plus ticagrelor after elective percutaneous coronary intervention
PACTR202606569630048Phase 4Completed
- Sponsor
- Al-Azhar University
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of aspirin, clopidogrel and ticagrelor in coronary arteriosclerosis (2 arms), sponsored by Al-Azhar University. Primary endpoints: Major adverse cardiac events and Major bleeding incident. Started Mar 2020; status: completed.
02
Drugs
aspirinclopidogrelticagrelor
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on PACTR202606569630048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606569630048.